NASDAQ:SLNO - Soleno Therapeutics Stock Price, Price Target & More

$1.81 +0.10 (+5.85 %)
(As of 04/26/2018 01:30 PM ET)
Previous Close$1.71
Today's Range$1.81 - $1.81
52-Week Range$1.32 - $3.75
Volume575 shs
Average Volume51,495 shs
Market Capitalization$34.22 million
P/E RatioN/A
Dividend YieldN/A
Beta5.04

About Soleno Therapeutics (NASDAQ:SLNO)

Soleno Therapeutics logoSoleno Therapeutics, Inc. focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company's lead candidate, diazoxide choline controlled-release (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is entering into Phase II/III clinical development. It also markets medical devices, including the CoSense End-Tidal Carbon Monoxide (ETCO) monitor, which measures ETCO and is used by hospitals to detect hemolysis in newborns; and NeoPip T-piece resuscitator and related consumables, which deliver consistent pre-set inspiratory pressure and positive end-expiratory pressures, as well as temperature probes, scales, surgical tables, and patient surfaces. In addition, the company offers Serenz, a handheld device that delivers non-inhaled carbon dioxide topically to the nasal mucosa. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. May 2017. Soleno Therapeutics, Inc. was founded in 1999 and is headquartered in Redwood City, California.

Receive SLNO News and Ratings via Email

Sign-up to receive the latest news and ratings for SLNO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SLNO
CUSIPN/A
Phone650-213-8444

Debt

Debt-to-Equity RatioN/A
Current Ratio10.40%
Quick Ratio10.40%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.45 million
Price / Sales24.33
Cash FlowN/A
Price / CashN/A
Book Value$1.38 per share
Price / Book1.31

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-15,660,000.00
Net MarginsN/A
Return on Equity-49.39%
Return on Assets-40.60%

Miscellaneous

Employees18
Outstanding Shares19,490,000

How to Become a New Pot Stock Millionaire

Soleno Therapeutics (NASDAQ:SLNO) Frequently Asked Questions

What is Soleno Therapeutics' stock symbol?

Soleno Therapeutics trades on the NASDAQ under the ticker symbol "SLNO."

When did Soleno Therapeutics' stock split? How did Soleno Therapeutics' stock split work?

Soleno Therapeutics's stock reverse split before market open on Friday, October 6th 2017. The 1-5 reverse split was announced on Thursday, October 5th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, October 5th 2017. An investor that had 100 shares of Soleno Therapeutics stock prior to the reverse split would have 20 shares after the split.

How were Soleno Therapeutics' earnings last quarter?

Soleno Therapeutics (NASDAQ:SLNO) posted its quarterly earnings data on Friday, August, 11th. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.10. View Soleno Therapeutics' Earnings History.

What price target have analysts set for SLNO?

1 Wall Street analysts have issued twelve-month price targets for Soleno Therapeutics' shares. Their predictions range from $4.00 to $4.00. On average, they expect Soleno Therapeutics' stock price to reach $4.00 in the next year. View Analyst Ratings for Soleno Therapeutics.

Who are some of Soleno Therapeutics' key competitors?

Who are Soleno Therapeutics' key executives?

Soleno Therapeutics' management team includes the folowing people:
  • Dr. Anish Bhatnagar, Pres, CEO, Principal Financial & Accounting Officer and Director (Age 48)
  • Mr. Anthony Wondka, Sr. VP of R&D (Age 56)
  • Mr. David D. O'Toole, Consultant (Age 59)
  • Mr. Jonathan R. Wolter, Interim Chief Financial Officer (Age 68)
  • Dr. Neil M. Cowen Ph.D., MBA, Sr. VP of Drug Devel.

Has Soleno Therapeutics been receiving favorable news coverage?

News coverage about SLNO stock has been trending somewhat negative recently, Accern Sentiment Analysis reports. The research group ranks the sentiment of news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Soleno Therapeutics earned a coverage optimism score of -0.10 on Accern's scale. They also assigned news stories about the company an impact score of 47.60 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

How do I buy shares of Soleno Therapeutics?

Shares of SLNO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Soleno Therapeutics' stock price today?

One share of SLNO stock can currently be purchased for approximately $1.81.

How big of a company is Soleno Therapeutics?

Soleno Therapeutics has a market capitalization of $34.22 million and generates $1.45 million in revenue each year. Soleno Therapeutics employs 18 workers across the globe.

How can I contact Soleno Therapeutics?

Soleno Therapeutics' mailing address is 1235 RADIO ROAD SUITE 110, REDWOOD CITY CA, 94065. The company can be reached via phone at 650-213-8444 or via email at [email protected]


MarketBeat Community Rating for Soleno Therapeutics (SLNO)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  126 (Vote Outperform)
Underperform Votes:  82 (Vote Underperform)
Total Votes:  208
MarketBeat's community ratings are surveys of what our community members think about Soleno Therapeutics and other stocks. Vote "Outperform" if you believe SLNO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SLNO will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Soleno Therapeutics (NASDAQ:SLNO) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
1 Wall Street analysts have issued ratings and price targets for Soleno Therapeutics in the last 12 months. Their average twelve-month price target is $4.00, suggesting that the stock has a possible upside of 120.99%. The high price target for SLNO is $4.00 and the low price target for SLNO is $4.00. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $4.00$4.00$8.00$25.00
Price Target Upside: 120.99% upside143.90% upside365.12% upside872.76% upside

Soleno Therapeutics (NASDAQ:SLNO) Consensus Price Target History

Price Target History for Soleno Therapeutics (NASDAQ:SLNO)

Soleno Therapeutics (NASDAQ:SLNO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/2/2018Maxim GroupSet Price TargetBuy$4.00HighView Rating Details
(Data available from 4/26/2016 forward)

Earnings

Soleno Therapeutics (NASDAQ:SLNO) Earnings History and Estimates Chart

Earnings by Quarter for Soleno Therapeutics (NASDAQ:SLNO)

Soleno Therapeutics (NASDAQ SLNO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/14/2017Q3 2017($0.24)ViewN/AView Earnings Details
8/11/2017Q2 2017($0.40)($0.30)ViewN/AView Earnings Details
5/11/2017Q1 2017($0.35)($0.55)$0.27 millionViewN/AView Earnings Details
3/15/2017Q4 2016($1.15)($0.82)$0.28 millionViewN/AView Earnings Details
11/14/2016Q3 2016($2.05)$0.33 millionViewN/AView Earnings Details
8/12/2016Q2($1.00)($1.15)$0.39 millionViewN/AView Earnings Details
5/10/2016Q115($1.35)($1.10)$0.45 millionViewN/AView Earnings Details
3/24/2016Q4($2.35)($1.10)$242.00 millionViewN/AView Earnings Details
11/12/2015Q3 2015($1.65)$0.25 millionViewN/AView Earnings Details
8/7/2015Q215($1.10)$1.25$0.10 millionViewN/AView Earnings Details
5/4/2015Q1 2015($8.35)$0.02 millionViewN/AView Earnings Details
3/10/2015Q4 2014($11.15)ViewN/AView Earnings Details
12/18/2014Q3 2014($22.35)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Soleno Therapeutics (NASDAQ:SLNO) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Soleno Therapeutics (NASDAQ SLNO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 69.75%
Institutional Ownership Percentage: 45.97%
Insider Trading History for Soleno Therapeutics (NASDAQ:SLNO)

Soleno Therapeutics (NASDAQ SLNO) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/15/2017Edgar EnglemanDirectorBuy1,085,480$1.84$1,997,283.20View SEC Filing  
8/19/2016Bhatnagar AnishInsiderBuy10,000$0.96$9,600.0083,419View SEC Filing  
8/18/2016David D O'tooleInsiderBuy2,000$1.01$2,020.0044,750View SEC Filing  
8/18/2016Ernest MarioDirectorBuy25,000$0.99$24,750.001,763,637View SEC Filing  
8/17/2016David D O'tooleInsiderBuy10,000$0.92$9,200.0042,750View SEC Filing  
6/8/2016Ernest MarioDirectorBuy50,000$1.24$62,000.001,918,637View SEC Filing  
5/23/2016Steinar J EngelsenDirectorBuy58,200$1.31$76,242.0080,960View SEC Filing  
5/20/2016Ernest MarioDirectorBuy48,806$1.18$57,591.081,863,000View SEC Filing  
5/13/2016Bhatnagar AnishCEOBuy5,000$1.15$5,750.0073,419View SEC Filing  
5/12/2016David D O'tooleInsiderBuy5,000$1.16$5,800.0032,750View SEC Filing  
11/18/2015Ernest MarioDirectorBuy50,000$1.77$88,500.001,639,831View SEC Filing  
11/17/2015David D O'tooleCFOBuy5,000$1.79$8,950.0027,750View SEC Filing  
9/14/2015David D O'tooleCFOBuy7,500$2.38$17,850.0022,750View SEC Filing  
9/14/2015Ernest MarioDirectorBuy15,000$2.28$34,200.001,589,831View SEC Filing  
3/13/2015David D O'tooleCFOBuy5,250$6.23$32,707.50View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Soleno Therapeutics (NASDAQ SLNO) News Headlines

Source:
DateHeadline
What Should You Know About Soleno Therapeutics Inc’s (NASDAQ:SLNO) Future?What Should You Know About Soleno Therapeutics Inc’s (NASDAQ:SLNO) Future?
finance.yahoo.com - April 4 at 8:50 AM
Capnia (SLNO) Given a $4.00 Price Target by Maxim Group AnalystsCapnia (SLNO) Given a $4.00 Price Target by Maxim Group Analysts
www.americanbankingnews.com - April 2 at 2:04 PM
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2017 Financial ResultsSoleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2017 Financial Results
globenewswire.com - April 2 at 9:12 AM
Does Soleno Therapeutics Inc’s (NASDAQ:SLNO) Past Performance Indicate A Weaker Future?Does Soleno Therapeutics Inc’s (NASDAQ:SLNO) Past Performance Indicate A Weaker Future?
finance.yahoo.com - March 27 at 9:05 AM
Soleno Therapeutics Inc (NASDAQ:SLNO): Is Breakeven Near?Soleno Therapeutics Inc (NASDAQ:SLNO): Is Breakeven Near?
finance.yahoo.com - March 17 at 8:58 AM
Contrasting Soleno Therapeutics (SLNO) & Cardiovascular Systems (CSII)Contrasting Soleno Therapeutics (SLNO) & Cardiovascular Systems (CSII)
www.americanbankingnews.com - March 10 at 3:34 AM
Soleno Therapeutics (SLNO) Given a $4.00 Price Target at Maxim GroupSoleno Therapeutics (SLNO) Given a $4.00 Price Target at Maxim Group
www.americanbankingnews.com - February 13 at 3:10 PM
Analyzing Tandem Diabetes Care (TNDM) and Soleno Therapeutics (SLNO)Analyzing Tandem Diabetes Care (TNDM) and Soleno Therapeutics (SLNO)
www.americanbankingnews.com - February 5 at 5:12 AM
Soleno Therapeutics (SLNO) Upgraded by ValuEngine to "Sell"Soleno Therapeutics (SLNO) Upgraded by ValuEngine to "Sell"
www.americanbankingnews.com - February 4 at 1:16 PM
BRIEF-Soleno Therapeutics Files For Resale Of Up To 14.2 Mln SharesBRIEF-Soleno Therapeutics Files For Resale Of Up To 14.2 Mln Shares
www.reuters.com - January 30 at 4:03 PM
Reviewing Soleno Therapeutics (SLNO) & Integra Lifesciences (IART)Reviewing Soleno Therapeutics (SLNO) & Integra Lifesciences (IART)
www.americanbankingnews.com - January 24 at 7:06 PM
BRIEF-Jack W. Schuler Living Trust Reports 13.4 Pct Stake In Soleno Therapeutics As Of December 15BRIEF-Jack W. Schuler Living Trust Reports 13.4 Pct Stake In Soleno Therapeutics As Of December 15
www.reuters.com - January 12 at 9:10 AM
BRIEF-Soleno Therapeutics Says Board Resolved To Decrease Size Of Board From Ten To SevenBRIEF-Soleno Therapeutics Says Board Resolved To Decrease Size Of Board From Ten To Seven
www.reuters.com - January 5 at 5:29 PM
Head-To-Head Analysis: Soleno Therapeutics (SLNO) and LDR (LDRH)Head-To-Head Analysis: Soleno Therapeutics (SLNO) and LDR (LDRH)
www.americanbankingnews.com - January 5 at 3:32 AM
Soleno Therapeutics, Inc. (SLNO)Soleno Therapeutics, Inc. (SLNO)
finance.yahoo.com - December 29 at 5:38 PM
Soleno Therapeutics (SLNO) vs. Its Rivals Head to Head ComparisonSoleno Therapeutics (SLNO) vs. Its Rivals Head to Head Comparison
www.americanbankingnews.com - December 22 at 9:20 PM
Head-To-Head Analysis: Soleno Therapeutics (SLNO) & Its PeersHead-To-Head Analysis: Soleno Therapeutics (SLNO) & Its Peers
www.americanbankingnews.com - December 22 at 1:24 PM
 Soleno Therapeutics Inc (SLNO) Given Consensus Rating of "Strong Buy" by Analysts Soleno Therapeutics Inc (SLNO) Given Consensus Rating of "Strong Buy" by Analysts
www.americanbankingnews.com - December 22 at 11:32 AM
Form 4 SOLENO THERAPEUTICS INC For: Dec 15 Filed by: ENGLEMAN EDGARForm 4 SOLENO THERAPEUTICS INC For: Dec 15 Filed by: ENGLEMAN EDGAR
www.streetinsider.com - December 21 at 9:00 AM
Soleno Therapeutics Inc (SLNO) Director Edgar Engleman Acquires 1,085,480 SharesSoleno Therapeutics Inc (SLNO) Director Edgar Engleman Acquires 1,085,480 Shares
www.americanbankingnews.com - December 19 at 11:32 PM
Reviewing Soleno Therapeutics (SLNO) & Its CompetitorsReviewing Soleno Therapeutics (SLNO) & Its Competitors
www.americanbankingnews.com - December 15 at 1:34 PM
Comparing Soleno Therapeutics (SLNO) & Its PeersComparing Soleno Therapeutics (SLNO) & Its Peers
www.americanbankingnews.com - December 15 at 5:30 AM
Financial Review: AtriCure (ATRC) vs. Soleno Therapeutics (SLNO)Financial Review: AtriCure (ATRC) vs. Soleno Therapeutics (SLNO)
www.americanbankingnews.com - December 14 at 3:30 AM
Capnia (SLNO) and Its Competitors Financial ReviewCapnia (SLNO) and Its Competitors Financial Review
www.americanbankingnews.com - December 12 at 11:04 AM
Soleno Therapeutics Announces $15 Million Private PlacementSoleno Therapeutics Announces $15 Million Private Placement
finance.yahoo.com - December 12 at 9:29 AM
Today’s Research Reports on Stocks to Watch: Soleno Therapeutics and La Jolla Pharmaceutical CompanyToday’s Research Reports on Stocks to Watch: Soleno Therapeutics and La Jolla Pharmaceutical Company
finance.yahoo.com - December 11 at 9:43 AM
Comparing Capnia (SLNO) and Its CompetitorsComparing Capnia (SLNO) and Its Competitors
www.americanbankingnews.com - December 10 at 9:30 AM
Capnia (SLNO) versus Its Competitors Head to Head SurveyCapnia (SLNO) versus Its Competitors Head to Head Survey
www.americanbankingnews.com - December 10 at 8:08 AM
Is Soleno Therapeutics Inc’s (SLNO) Balance Sheet Strong Enough To Weather A Storm?Is Soleno Therapeutics Inc’s (SLNO) Balance Sheet Strong Enough To Weather A Storm?
finance.yahoo.com - December 9 at 9:01 AM
Maxim Group Reiterates "$8.00" Price Target for Capnia (SLNO)Maxim Group Reiterates "$8.00" Price Target for Capnia (SLNO)
www.americanbankingnews.com - December 8 at 7:38 PM
Financial Analysis: Capnia (SLNO) versus Its CompetitorsFinancial Analysis: Capnia (SLNO) versus Its Competitors
www.americanbankingnews.com - December 3 at 1:36 PM
Should Soleno Therapeutics Inc’s (SLNO) Earnings Decline In Recent Times Worry You?Should Soleno Therapeutics Inc’s (SLNO) Earnings Decline In Recent Times Worry You?
finance.yahoo.com - November 30 at 5:44 PM
 Capnia, Inc. (SLNO) Receives Consensus Recommendation of "Strong Buy" from Analysts Capnia, Inc. (SLNO) Receives Consensus Recommendation of "Strong Buy" from Analysts
www.americanbankingnews.com - November 30 at 1:28 AM
Analyzing Capnia (SLNO) and Its CompetitorsAnalyzing Capnia (SLNO) and Its Competitors
www.americanbankingnews.com - November 23 at 9:32 AM
Soleno Therapeutics to Present at the Piper Jaffray 29th Annual Healthcare ConferenceSoleno Therapeutics to Present at the Piper Jaffray 29th Annual Healthcare Conference
finance.yahoo.com - November 22 at 8:06 AM
 Cuts Capnia, Inc. (SLNO) Price Target to $8.00 Cuts Capnia, Inc. (SLNO) Price Target to $8.00
www.americanbankingnews.com - November 19 at 4:56 PM
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2017 Financial ResultsSoleno Therapeutics Provides Corporate Update and Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 15 at 9:27 AM
What Is Soleno Therapeutics Inc’s (SLNO) Share Price Doing?What Is Soleno Therapeutics Inc’s (SLNO) Share Price Doing?
finance.yahoo.com - November 15 at 9:27 AM
Maxim Group Lowers Capnia, Inc. (SLNO) Price Target to $8.00Maxim Group Lowers Capnia, Inc. (SLNO) Price Target to $8.00
www.americanbankingnews.com - November 14 at 4:40 PM
Soleno Therapeutics Regains Compliance with NASDAQ Listing RequirementsSoleno Therapeutics Regains Compliance with NASDAQ Listing Requirements
finance.yahoo.com - October 24 at 10:02 AM
Head to Head Contrast: SeaSpine Holdings Corporation (SPNE) and Capnia (SLNO)Head to Head Contrast: SeaSpine Holdings Corporation (SPNE) and Capnia (SLNO)
www.americanbankingnews.com - October 21 at 4:34 PM
Maxim Group Reiterates $25.00 Price Target for Capnia, Inc. (SLNO)Maxim Group Reiterates $25.00 Price Target for Capnia, Inc. (SLNO)
www.americanbankingnews.com - October 13 at 12:32 AM
Soleno Therapeutics Announces Issuance of New U.S. Patent for DCCR Covering Treatment of Hyperphagia in Prader-Willi SyndromeSoleno Therapeutics Announces Issuance of New U.S. Patent for DCCR Covering Treatment of Hyperphagia in Prader-Willi Syndrome
finance.yahoo.com - October 12 at 9:36 AM
Soleno Therapeutics Receives Positive Opinion from European Orphan Committee for DCCR in Prader-Willi SyndromeSoleno Therapeutics Receives Positive Opinion from European Orphan Committee for DCCR in Prader-Willi Syndrome
finance.yahoo.com - October 12 at 9:36 AM
Capnia, Inc. (SLNO) Upgraded by ValuEngine to SellCapnia, Inc. (SLNO) Upgraded by ValuEngine to Sell
www.americanbankingnews.com - October 6 at 10:34 PM
Soleno Therapeutics Announces 1-for-5 Reverse Stock SplitSoleno Therapeutics Announces 1-for-5 Reverse Stock Split
finance.yahoo.com - October 6 at 11:04 AM
Contrasting Invacare Corporation (IVC) and Capnia (SLNO)Contrasting Invacare Corporation (IVC) and Capnia (SLNO)
www.americanbankingnews.com - October 6 at 2:08 AM
Soleno Therapeutics Announces Receipt of Scientific Advice from the European Medicines Agency for DCCR in Prader-Willi SyndromeSoleno Therapeutics Announces Receipt of Scientific Advice from the European Medicines Agency for DCCR in Prader-Willi Syndrome
finance.yahoo.com - September 26 at 4:58 PM
Orthofix International N.V. (OFIX) vs. Soleno Therapeutics (SLNO) Head-To-Head AnalysisOrthofix International N.V. (OFIX) vs. Soleno Therapeutics (SLNO) Head-To-Head Analysis
www.americanbankingnews.com - September 20 at 2:08 AM
Soleno Therapeutics Presents Updated Safety and Efficacy Data from Clinical Trial of DCCR for Treatment of Prader-Willi SyndromeSoleno Therapeutics Presents Updated Safety and Efficacy Data from Clinical Trial of DCCR for Treatment of Prader-Willi Syndrome
finance.yahoo.com - September 15 at 9:02 AM

SEC Filings

Soleno Therapeutics (NASDAQ:SLNO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Soleno Therapeutics (NASDAQ:SLNO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Soleno Therapeutics (NASDAQ SLNO) Stock Chart for Thursday, April, 26, 2018

Loading chart…

This page was last updated on 4/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.